Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Johnson and Johnson
Baxter
Merck
McKesson

Last Updated: May 28, 2022

Investigational Drug Information for GBT440


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug GBT440?

GBT440 is an investigational drug.

There have been 19 clinical trials for GBT440. The most recent clinical trial was a Phase 3 trial, which was initiated on September 21st 2020.

The most common disease conditions in clinical trials are Anemia, Sickle Cell, Hypoxia, and Fibrosis. The leading clinical trial sponsors are Global Blood Therapeutics, National Heart, Lung, and Blood Institute (NHLBI), and Elizabeth Yang, MD, PhD.

There are eighteen US patents protecting this investigational drug and two hundred and ninety-three international patents.

Recent Clinical Trials for GBT440
TitleSponsorPhase
Hemolysis Related Complications in SCD. A Phase II Study With VoxelotorGlobal Blood Therapeutics (GBT)Phase 2
Hemolysis Related Complications in SCD. A Phase II Study With VoxelotorAssistance Publique - Hôpitaux de ParisPhase 2
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell DiseaseGlobal Blood TherapeuticsPhase 3

See all GBT440 clinical trials

Clinical Trial Summary for GBT440

Top disease conditions for GBT440
Top clinical trial sponsors for GBT440

See all GBT440 clinical trials

US Patents for GBT440

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GBT440 See Plans and Pricing Methods of treatment Global Blood Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
GBT440 See Plans and Pricing Compounds and uses thereof for the modulation of hemoglobin Global Blood Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
GBT440 See Plans and Pricing Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation Global Blood Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
GBT440 See Plans and Pricing Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzal- dehyde Global Blood Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
GBT440 See Plans and Pricing Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde Global Blood Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
GBT440 See Plans and Pricing Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde Global Blood Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
GBT440 See Plans and Pricing Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzal- dehyde Global Blood Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GBT440

Drugname Country Document Number Estimated Expiration Related US Patent
GBT440 Australia AU2016243428 2035-03-30 See Plans and Pricing
GBT440 Brazil BR112017020276 2035-03-30 See Plans and Pricing
GBT440 Canada CA2980578 2035-03-30 See Plans and Pricing
GBT440 Chile CL2017002435 2035-03-30 See Plans and Pricing
GBT440 China CN107531671 2035-03-30 See Plans and Pricing
GBT440 Eurasian Patent Organization EA201791998 2035-03-30 See Plans and Pricing
GBT440 European Patent Office EP3277379 2035-03-30 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Johnson and Johnson
Baxter
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.